EBV-Associated Lymphoma Consortium Annual Meeting (Abstract)

Abstract Submission

Submission information

Submission Number: 2

Submission ID: 149987

Submission UUID: 26f0bb87-964e-4198-b235-fb2b0bb26c4c

Submission URI: /nci/ealv/venue/abstract

Submission Update: /nci/ealv/venue/abstract?token=HcZ7rSyNm5q7L9FJYJEunhxwYiWqH_hZnzc8ZvqUUIA

Created: Wed, 08/27/2025 - 11:58

Completed: Wed, 08/27/2025 - 11:58

Changed: Wed, 08/27/2025 - 11:58

Remote IP address: 10.208.24.239

Submitted by: Anonymous

Language: English

Is draft: No

Webform: EBV-Associated Lymphoma Consortium Annual Meeting (Abstracts)

Submitted to: EBV-Associated Lymphoma Consortium Annual Meeting (Abstract)

OMB No.: 0925-0740
Expiration Date: 9/30/2025

Public reporting burden for this collection of information is estimated to average 60 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.

Presenter Information

Please enter information for the person who will be the primary presenter/speaker/author.

First Name

Middle Initial

Last Name

Degree(s)

Please use the following formatting for these degrees: M.D. Ph.D. MPH

Position/Title/Career Status

Organization

Organization City/Town

Please provide a contact email for conference organizers to reach you.

Abstract Information

Abstract Keywords

Up to five keywords of your choice

Abstract Title

Abstract Summary

One major focus of this project is to investigate the impact of LMP2A on the pathogenesis of EBV-driven lymphoma using a "humanized" mouse xenograft model. We compared mice transplanted with cord blood mononuclear cells infected with WT or LMP2A-deleted (ΔLMP2A) EBV (M81 strain). Similar to published findings, we observed that ΔLMP2A and WT initially led to similar tumor size and incidence. However, ΔLMP2A tumors failed to progress in size over time and were much less invasive, significantly decreasing mortality in those mice. In both WT and ΔLMP2A mice we observed two distinct subsets of B cells: plasmablastic (CD38hi/CD20lo) and less differentiated CD20hi/CD38lo. In pre-invasive tumors, plasmablastic cells formed capsule-like structures at the leading edge of the tumor, while the less differentiated cells clustered at the center. As tumors progressed, plasmablastic cells were the first to invade organ tissue. These findings led us to further investigate the invasive quality of these plasmablastic cells. 
In RNA-Seq analysis of LCLs controlled for BCR isotype to isolate the effect of LMP2A, we found that WT LCLs upregulated many genes associated with plasma cell differentiation compared to ΔLMP2A LCLs. Published work has established a gradient of proliferation and differentiation in LCLs and identified LMP1 as the driver of proliferation. We hypothesize that LMP2A is responsible for differentiation. We believe this gradient can be explained by the bi-directional ED-L1 promoter, which drives expression of both LMP1 and LMP2B. When ED-L1 activity is high, LMP1 drives proliferation and the NF-kB pathway, and LMP2B diminishes signaling activity of LMP2A, leading to decreased differentiation. While these results clarify the impact of LMP2A on plasmablastic cell differentiation, the factor(s) regulating invasion remain unknown. Ongoing studies aim to identify the switch that regulates plasmablastic cell invasion.